{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T21:32:32Z","timestamp":1765143152439,"version":"3.40.5"},"reference-count":19,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,1]]},"abstract":"<jats:p>An 8-year-old boy with hypoplastic left heart syndrome with a previous history of thrombosis within the inferior vena cava receiving stable warfarin dosing for anticoagulation was diagnosed with influenza B. He was subsequently placed on oseltamivir therapy according to the Centers for Disease Control and Prevention clinical practice guidelines. During the hospitalization, his international normalized ratio steadily increased to supratherapeutic levels and returned to baseline after discontinuation of oseltamivir therapy. This case represents a drug-drug interaction that has not been previously reported in children or adolescents. An extensive review of the pharmacokinetic and pharmacodynamic literature did not uncover a definitive etiology for this interaction. However, several undefined aspects in each drug\u2019s disposition pathway need further elucidation. Until this interaction is understood, caution is warranted, and close monitoring of the international normalized ratio should be performed in all patients prescribed oseltamivir concomitantly with warfarin.<\/jats:p>","DOI":"10.1542\/peds.2014-2578","type":"journal-article","created":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:32:43Z","timestamp":1430181163000},"page":"e1333-e1336","source":"Crossref","is-referenced-by-count":8,"title":["Oseltamivir-Warfarin Interaction in Hypoplastic Left Heart Syndrome: Case Report and Review"],"prefix":"10.1542","volume":"135","author":[{"given":"Jonathan","family":"Wagner","sequence":"first","affiliation":[{"name":"Section of Cardiology, and"},{"name":"Division of Clinical Pharmacology, Medical Toxicology and Therapeutic Innovation, Children\u2019s Mercy Hospital, Kansas City, Missouri; and"},{"name":"Department of Pediatrics, University of Missouri\u2013Kansas City School of Medicine, Kansas City, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"Abdel-Rahman","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Medical Toxicology and Therapeutic Innovation, Children\u2019s Mercy Hospital, Kansas City, Missouri; and"},{"name":"Department of Pediatrics, University of Missouri\u2013Kansas City School of Medicine, Kansas City, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2015,5,1]]},"reference":[{"issue":"18","key":"2021120907094615800_B1","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJM199910283411802","article-title":"Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.","volume":"341","author":"Hayden","year":"1999","journal-title":"N Engl J Med"},{"issue":"13","key":"2021120907094615800_B2","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jama.282.13.1240","article-title":"Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.","volume":"282","author":"Hayden","year":"1999","journal-title":"JAMA"},{"issue":"5","key":"2021120907094615800_B3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/infdis\/jis765","article-title":"Oseltamivir pharmacokinetics, dosing, and resistance among children aged &lt;2 years with influenza.","volume":"207","author":"Kimberlin","year":"2013","journal-title":"J Infect Dis"},{"issue":"3","key":"2021120907094615800_B4","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1124\/jpet.106.111807","article-title":"Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel.","volume":"319","author":"Shi","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"2021120907094615800_B5","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1128\/AAC.01541-08","article-title":"Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.","volume":"53","author":"Hoffmann","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2021120907094615800_B6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-199937060-00003","article-title":"Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.","volume":"37","author":"He","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"2021120907094615800_B7"},{"issue":"2","key":"2021120907094615800_B8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/11595860-000000000-00000","article-title":"Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review.","volume":"32","author":"Lee","year":"2012","journal-title":"Clin Drug Investig"},{"issue":"6","key":"2021120907094615800_B9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1365-2125.2010.03780.x","article-title":"Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients.","volume":"70","author":"Davies","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2021120907094615800_B10","first-page":"623","article-title":"Novel H1N1 influenza A viral infection complicated by alveolar hemorrhage.","volume":"55","author":"Gilbert","year":"2010","journal-title":"Respir Care"},{"issue":"5","key":"2021120907094615800_B11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2169\/internalmedicine.49.3022","article-title":"Acute lung injury with alveolar hemorrhage due to a novel swine-origin influenza A (H1N1) virus.","volume":"49","author":"Yokoyama","year":"2010","journal-title":"Intern Med"},{"issue":"7","key":"2021120907094615800_B12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archinternmed.2010.49","article-title":"Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study.","volume":"170","author":"Iorio","year":"2010","journal-title":"Arch Intern Med"},{"issue":"5","key":"2021120907094615800_B13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2710.2012.01341.x","article-title":"Effect of influenza vaccination on international normalized ratio during chronic warfarin therapy.","volume":"37","author":"Kuo","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"2021120907094615800_B14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev.me.27.020176.001333","article-title":"Vitamin K and the oral anticoagulant drugs.","volume":"27","author":"O\u2019Reilly","year":"1976","journal-title":"Annu Rev Med"},{"issue":"3","key":"2021120907094615800_B15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00008571-200204000-00010","article-title":"Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.","volume":"12","author":"Lee","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"6","key":"2021120907094615800_B16","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/ajcn\/67.6.1226","article-title":"Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans.","volume":"67","author":"Lamon-Fava","year":"1998","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"2021120907094615800_B17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.tpj.6500313","article-title":"Common VKORC1 and GGCX polymorphisms associated with warfarin dose.","volume":"5","author":"Wadelius","year":"2005","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"2021120907094615800_B18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/clpt.2011.185","article-title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.","volume":"90","author":"Johnson","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2021120907094615800_B19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-0038-1642427","article-title":"Oral anticoagulation therapy in pediatric patients: a prospective study.","volume":"71","author":"Andrew","year":"1994","journal-title":"Thromb Haemost"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/135\/5\/e1333\/1093629\/peds_2014-2578.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/135\/5\/e1333\/1093629\/peds_2014-2578.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T01:37:32Z","timestamp":1639100252000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/135\/5\/e1333\/33638\/Oseltamivir-Warfarin-Interaction-in-Hypoplastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,1]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,1]]},"published-print":{"date-parts":[[2015,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2014-2578","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2015,5,1]]}}}